Articles by tag: biotech-analysis

Novavax shares rose 35% — risk and outlook analysis

Analysis of Novavax stock surge after EU vaccine approval: real risks, hidden facts, and forecast for investors. Read analysis before buying.

VERVE-102 gene editing reduces cholesterol by 62% — analysis

Phase 1 results of VERVE-102: sustained LDL-C reduction up to 62% in patients with hypercholesterolemia. Analysis of market implications and forecasts. Read more.